Safety, Immunogenicity, and Efficacy of Intramuscular and Oral Delivery of ERA-G333 Recombinant Rabies Virus Vaccine to Big Brown Bats (\u3ci\u3eEptesicus fuscus\u3c/i\u3e) by Gilbert, Amy T. et al.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
USDA National Wildlife Research Center - Staff 
Publications 
U.S. Department of Agriculture: Animal and 
Plant Health Inspection Service 
2020 
Safety, Immunogenicity, and Efficacy of Intramuscular and Oral 
Delivery of ERA-G333 Recombinant Rabies Virus Vaccine to Big 
Brown Bats (Eptesicus fuscus) 
Amy T. Gilbert 
USDA National Wildlife Research Center, amy.t.gilbert@usda.gov 
Xianfu Wu 
Centers for Disease Control and Prevention 
Felix R. Jackson 
Centers for Disease Control and Prevention 
Richard Franka 
Centers for Disease Control and Prevention 
Gary F. McCracken 
University of Tennessee 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.unl.edu/icwdm_usdanwrc 
 Part of the Natural Resources and Conservation Commons, Natural Resources Management and 
Policy Commons, Other Environmental Sciences Commons, Other Veterinary Medicine Commons, 
Population Biology Commons, Terrestrial and Aquatic Ecology Commons, Veterinary Infectious Diseases 
Commons, Veterinary Microbiology and Immunobiology Commons, Veterinary Preventive Medicine, 
Epidemiology, and Public Health Commons, and the Zoology Commons 
Gilbert, Amy T.; Wu, Xianfu; Jackson, Felix R.; Franka, Richard; McCracken, Gary F.; and Rupprecht, Charles 
E., "Safety, Immunogenicity, and Efficacy of Intramuscular and Oral Delivery of ERA-G333 Recombinant 
Rabies Virus Vaccine to Big Brown Bats (Eptesicus fuscus)" (2020). USDA National Wildlife Research 
Center - Staff Publications. 2366. 
https://digitalcommons.unl.edu/icwdm_usdanwrc/2366 
This Article is brought to you for free and open access by the U.S. Department of Agriculture: Animal and Plant 
Health Inspection Service at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion 
in USDA National Wildlife Research Center - Staff Publications by an authorized administrator of 
DigitalCommons@University of Nebraska - Lincoln. 
Authors 
Amy T. Gilbert, Xianfu Wu, Felix R. Jackson, Richard Franka, Gary F. McCracken, and Charles E. Rupprecht 
This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
icwdm_usdanwrc/2366 
DOI: 10.7589/2019-04-108 Journal of Wildlife Diseases, 56(3), 2020, pp. 620–630
 Wildlife Disease Association 2020
SAFETY, IMMUNOGENICITY, AND EFFICACY OF INTRAMUSCULAR
AND ORAL DELIVERY OF ERA-G333 RECOMBINANT RABIES VIRUS
VACCINE TO BIG BROWN BATS (EPTESICUS FUSCUS)
Amy T. Gilbert,1,2,5 Xianfu Wu,1 Felix R. Jackson,1 Richard Franka,3 Gary F. McCracken,2 and
Charles E. Rupprecht4
1 Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control
and Prevention, 1600 Clifton Rd. NE, Atlanta, Georgia 30333, USA
2 Department of Ecology and Evolutionary Biology, University of Tennessee, 1416 Circle Dr., Knoxville, Tennessee
37996, USA
3 Center for Global Health, Global Immunization Division, Centers for Disease Control and Prevention, 1600 Clifton Rd.
NE, Atlanta, Georgia 30333, USA
4 LYSSA LLC, 309 Pirkle Ferry Rd., Suite D300, Cumming, Georgia 30040, USA
5 Corresponding author (email: amy.t.gilbert@usda.gov)
ABSTRACT: Attenuated strains of rabies virus (RABV) have been used for oral vaccination of wild
carnivores in Europe and North America. However, some RABV vaccines caused clinical rabies in
target animals. To improve the safety of attenuated RABV as an oral vaccine for field use, strategies
using selection of escape mutants under monoclonal antibody neutralization pressure and reverse
genetics–defined mutations have been used. We tested the safety, immunogenicity, and efficacy of one
RABV construct, ERA-g333, developed with reverse genetics by intramuscular (IM) or oral (PO) routes
in big brown bats (Eptesicus fuscus). Twenty-five bats received 53106 mouse intracerebral median
lethal doses (MICLD50) of ERA-g333 by IM route, 10 received 5310
6 MICLD50 of ERA-g333 by PO
route, and 22 bats served as unvaccinated controls. Twenty-one days after vaccination, 44 bats were
infected by IM route with 102.9 MICLD50 of E. fuscus RABV. We report both the immunogenicity and
efficacy of ERA-g333 delivered by the IM route; no induction of humoral immunity was detected in
bats vaccinated by the PO route. Two subsets of bats vaccinated IM (n¼5) and PO (n¼3) were not
challenged, and none developed clinical rabies from ERA-g333. Scarce reports exist on the evaluation
of oral rabies vaccines in insectivorous bats, although the strategy evaluated here may be feasible for
future application to these important RABV reservoirs.
Key words: Bat, Eptesicus fuscus, ERA, rabies, reverse genetics, vaccination.
INTRODUCTION
Rabies is a zoonotic disease caused by
infection with negative-sense, single-stranded
RNA viruses in the genus Lyssavirus. Rabies
virus (RABV) is responsible for an estimated
.59,000 human fatalities each year world-
wide, the majority of which are transmitted
through bites by rabid dogs (Hampson et al.
2015). In the Americas, bats are also an
important RABV reservoir for human and
animal infections (Messenger et al. 2002;
Schneider et al. 2009). While the common
vampire bat (Desmodus rotundus) is the most
important RABV reservoir of human and
animal infections in Latin America, insectiv-
orous bat RABV is associated with the
majority of human infections, as well as
spillover and epizootic events in wild carni-
vores in Canada and the US (Leslie et al.
2006; De Serres et al. 2008; Kuzmin et al.
2012). The highest diversity of sylvatic RABV
reservoirs is found in the Americas, in part
due to the independent circulation of RABV
in multiple insectivorous bat species (Gilbert
2018). The most widely employed modern
method for wildlife RABV control is a strategy
of oral rabies vaccination (ORV; World Health
Organization 2018). Because ORV efforts
primarily target wild carnivore RABV reser-
voirs, few studies have evaluated oral rabies
vaccines in bats.
The Evelyn-Rokitniki-Abelseth (ERA)
strain of RABV is an attenuated virus that
was derived from the Street-Alabama-Duffer-
in RABV strain. Both RABV strains have been
used for ORV in carnivore reservoirs in North
America and Europe (MacInnes et al. 2001;
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Muller et al. 2015), yet cases of residual
pathogenicity have been reported after the
field use in target and nontarget animals
(Fehlner-Gardiner et al. 2008; Vuta et al.
2016). One study demonstrated that the
pathogenicity of the ERA strain can be
significantly altered by mutations at amino
acid residue 333 of the glycoprotein (Die-
tzschold et al. 1983). Escape mutants of the
Street-Alabama-Dufferin virus strain were
produced under monoclonal antibody selec-
tion pressure at position 333 and identified as
SAG1 and SAG2 (Le Blois et al. 1990; Lafay et
al. 1994), the latter of which has also been
widely used for ORV of wildlife in Europe
(Mähl et al. 2014). Site-directed mutagenesis
was also utilized to alter all three nucleotides
at position 333 of the ERA glycoprotein gene
(ERA-g333) to further improve the safety
profile by reducing the chance for reversion to
a virulent phenotype. Experimental studies
have demonstrated the safety, immunogenic-
ity, and efficacy of this construct for laboratory
animal models and nonhuman primates, red
foxes (Vulpes vulpes), gray foxes (Urocyon
cinereoargenteus), and raccoon dogs (Nycter-
eutes procyonoides; Bankovskiy et al. 2008;
Franka et al. 2009; Wu et al. 2011; Smith et al.
2017). A similar construct was also reported to
be safe, immunogenic, and efficacious by
intramuscular and oral delivery for domestic
dogs (immunogenicity only) and raccoon dogs
(Yang et al. 2014, 2015, 2016). No studies to
our knowledge have examined ERA or its
derivatives in bats.
The objective of this study was to evaluate
experimentally the relative safety, immunoge-
nicity, and efficacy of ERA-g333, delivered by
the intramuscular (IM) and oral (PO) routes,
against a lethal RABV infection in big brown
bats (Eptesicus fuscus).
MATERIALS AND METHODS
Animals and housing
Experimental procedures and animal care were
performed in compliance with the Centers for
Disease Control and Prevention (CDC) Institu-
tional Animal Care and Use Committee guide-
lines (protocol 1405RUPBATL). During June and
September 2007, 57 big brown bats were
collected using butterfly nets from a building
roost in Georgia, as authorized by Georgia
Department of Natural Resources Scientific
Collection permit 29-WCH-07-54. Bats were held
captive in quarantine at the CDC for at least 1 mo
prior to use and marked individually with metal
bands on the forearm. During quarantine and
acclimation, bats were trained to eat commercial
live mealworms (Tenebrio molitor) from petri
dishes. For the duration of the experiment,
individual petri dishes of water and mealworms
were offered ad libitum to each cage of bats and
refreshed daily. Eleven groups of bats were
housed separately in 81333053254 mm stain-
less-steel cages, with all cages held in a room at
24–27 C and about 30% humidity. Two cages (N,
O) held groups of six bats, and the remaining nine
cages (L, M, P, Q, R, S, T, U, V) held groups of
five bats (see Supplementary Material Table S1).
Baseline sera were collected to screen the RABV
exposure status of bats prior to vaccination.
Vaccination
The ERA-g333 vaccine used for these experi-
ments has been previously described (Bankovskiy
et al. 2008). Bats were manually restrained and
administered 53106 focus-forming units (FFU) of
ERA-g333 (0.05 mL of 108 FFU/mL) by IM
(n¼25) or PO (n¼10) routes, replicated as two
consecutive experiments. Unvaccinated control
bats (n¼22) were not mock treated. The volume
used was appropriate for our 15–20 g subjects
(Stading et al. 2017). Vaccine treatments were
assigned to replicate cages of bats. On day 0, 25
bats were vaccinated by IM route in the deltoid
muscle, and 10 bats were vaccinated by PO route
using a needless syringe. The PO delivery of
vaccine was made by depositing droplets into the
open mouth of the manually restrained bat,
allowing the bat time to swallow between
droplets. Seventeen bats served as unvaccinated
controls and were held in separate cages from
vaccinated bats. Five bats served as unvaccinated
and uninfected contact controls with orally
vaccinated (n¼2, cages N and O) and unvaccinat-
ed control bats (n¼3, cage P) during experiment 1.
No contact controls were held during experiment
2.
Blood samples were obtained from a peripheral
wing vein during each experiment or by the
intracardiac route for terminal exsanguination
under heavy anesthesia during euthanasia (Voigt
and Cruz-Neto 2009), and these samples were
collected in sterile heparinized microcapillary
tubes. Serum was separated by low-speed centri-
fugation and stored at 20 C until processing.
Bats were bled at similar intervals, including days
5, 14, 27, 43, 98, and 155 postvaccination (PV)
GILBERT ET AL.—ERA-G333 SAFETY AND EFFICACY IN BATS 621
during experiment 1 and days 5, 19, 34, 49, 90,
and 161 PV during experiment 2.
RABV challenge
The E. fuscus RABV used for challenge was
collected from the salivary glands of a naturally
infected big brown bat in Pennsylvania during
2006 (PAEf3684; CDC accession no. A06-3684),
as described previously (Turmelle et al. 2010). On
day 21 PV, bats were restrained manually and
inoculated by IM route into both the left and right
masseter muscles with 104.2 mouse intracerebral
median lethal dose (MICLD50)/mL of RABV in a
volume of 0.05 mL. Twenty-seven vaccinates were
challenged across two experiments, including 20
bats vaccinated by IM and seven bats vaccinated
by PO. In total, 17 unvaccinated bats were
challenged as controls across two experiments.
Animals were monitored daily for clinical signs of
rabies for 140 d postinfection (PI).
Bats were subjected to exsanguination under
heavy anesthesia and euthanized by intracardiac
injection of a barbiturate solution (i.e., pentobar-
bital sodium and phenytoin sodium), upon
presentation of two or more definitive clinical
signs of RABV infection (e.g., increased aggres-
sion/reclusion, acute weight loss, ataxia, atypical
vocalizations, paresis, or paralysis). Brain tissue
was collected and tested for RABV antigen by the
direct fluorescent antibody (DFA) test (Dean et
al. 1996), using fluorescein isothiocyanate–labeled
monoclonal antibody conjugate (Fujirebio Diag-
nostics, Inc., Malvern, Pennsylvania, USA). For all
rabid bats, total RNA was extracted from individ-
ual brain tissues, and the RABV nucleoprotein
gene was amplified and sequenced (Trimarchi
and Smith 2002).
Detection of RABV-neutralizing antibodies
A modified rapid fluorescent focus inhibition
test (Jackson et al. 2008), using RABV challenge
virus standard (CVS-11), was used to assay for
RABV-specific viral-neutralizing antibodies
(RVNA) in the blood plasma of individual bats.
Titers were calculated by the Reed-Muench
method (Reed and Muench 1938), and values
were converted to international units (IU/mL) by
comparison to the US Standard Rabies Immune
Globulin (Laboratory of Standards and Testing,
Food and Drug Administration, Bethesda, Mary-
land, USA) diluted to 2 IU/mL. The RVNA titers
of individual bats were determined up to a level of
9.14 IU/mL, equivalent to 50% neutralization at
the eighth serial twofold dilution. The minimum
level of RVNA detection in the modified rapid
fluorescent focus inhibition test was defined as
0.06 IU/mL, as reported previously (Turmelle et
al. 2010). In this study, values 0.1 IU/mL were
considered as evidence of neutralization, which
was equivalent to a titer of about 1/22. Titers at or
above the cutoff of 0.1 IU/mL that exhibited a
fourfold increase or greater above baseline values
were considered as evidence of seroconversion PV
or PI.
Statistical analysis
The RVNA titers that exceeded 9.14 IU/mL
were coded as 9.14 IU/mL for the purpose of
geometric mean calculations. Group geometric
mean titers were calculated for different treat-
ment groups, but they excluded bats that were
seropositive upon baseline sampling as well as
unvaccinated control bats in cage U. The survival
fraction and 95% exact confidence interval (CI)
were calculated among vaccine treatment and
unvaccinated groups of RABV-challenged bats. A
survival analysis was also performed among
challenged bats to test for homogeneity in survival
curves PI, using a log-rank test on data stratified
by vaccine treatment and route and the Šidák
correction to adjust for multiple pairwise com-
parisons. SAS version 9.4 was used to perform all
analyses (SAS Institute, Cary, North Carolina,
USA), and significance was assessed at a¼0.05.
RESULTS
In total, 57 individual big brown bats were
included in the study (Table 1; Supplementary
Material Table S1). Three bats (#42, 54, 72)
presented evidence of RVNA during baseline
sampling and were treated as contact controls
during experiment 1 (cage P). On day 98 PV
of experiment 1, they were kept in the same
cage but challenged with RABV as part of
experiment 2. Two other bats (#31 and 33)
were used as contact controls in separate
cages during experiment 1, but neither
demonstrated evidence of RVNA during the
study (Supplementary Material Table S1;
serology data not shown). These bats were
censored during experiment 1 on days 118
(#31) and 161 (#33) PV and were not used
during experiment 2.
Vaccination
In the group of 25 bats vaccinated by IM
route, three bats presented evidence of RVNA
at baseline (#10, 23, 29; Table 2). Among 22
bats vaccinated by IM route that were
seronegative at baseline, a moderate propor-
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tion had seroconverted by days 14–19 PV
(60%, 12/20; Table 2), whereas evidence of
seroconversion prior to challenge on day 21
PV could not be determined for two bats (#15,
22). The RVNA geometric mean titers among
the 22 bats that were seronegative at baseline
and vaccinated by IM was 0.39 IU/mL on days
14–19 PV. Although eight bats did not
seroconvert prior to challenge on day 21 PV
(#12, 14, 19, 20, 25, 26, 39, 47), only two bats
(#19, 25) remained seronegative PV until
being censored from study on days 27 and
125 PV. Four (#14, 38, 41, 51) IM vaccinates
that were seronegative at baseline demon-
strated RVNA as early as day 5 PV, suggestive
of prior RABV exposure history. No RVNA
were detected during the baseline sampling of
10 bats vaccinated by PO route, and none of
these bats seroconverted during the study
(Table 3). No adverse events related to
vaccination were noted in any subjects (e.g.,
reversion to virulence). Only one bat of the
unvaccinated control group demonstrated
RVNA during baseline sampling (#21, cage
U; Table 4) and prior to challenge.
RABV challenge
Two of the three bats (#10, 23) vaccinated
by IM route and presenting RVNA upon
baseline sampling were challenged, and both
survived along with 18 bats vaccinated by IM
route that were seronegative prior to vaccina-
tion (Table 5 and Fig. 1). All bats that were
seronegative at baseline and vaccinated by IM
route were protected against rabies infection
(17/17, 95% CI 82–100), excluding one bat
(#19) censored on day 27 PV. Survival among
bats vaccinated by PO route was 57% (4/7,
95% CI 25–84). Three bats vaccinated by PO
route developed clinical rabies and were
euthanized on days 24, 26, and 87 PI,
respectively. Among unvaccinated controls,
we retroactively diagnosed an outbreak of
natural infection among bats in cage U, and
these five bats were excluded from the
analysis (see Supplementary Material Table
S2). The remaining 12 unvaccinated controls
were seronegative during the study, except for
one bat (#35) that presented RVNA on day 6
PI, perhaps suggestive of a prior RABV
exposure history. Survival among unvaccinat-
ed controls was 44% (4/9, 95% CI 19–73) with
a median incubation period of 26 d (range:
20–115 d), excluding two censored bats and
one bat missing a diagnostic DFA result. The
three seropositive contact controls from cage
P survived RABV challenge during experi-
ment 2, although there was equivocal evi-
dence for a boosting effect of challenge on
RVNA levels PI (Table 6). The IM vaccinate
group had greater survival compared to both
the PO vaccinate group (v2¼8.5, P¼0.01) and
unvaccinated controls (v2¼9.7, P¼0.006), but
there was no difference in survival between
the PO vaccinates and unvaccinated controls
(v2¼0.5, P¼0.86).
Detection of naturally infected bats
The first rabid bat from cage U (unvacci-
nated controls) was found dead in its cage on
TABLE 1. Study design of two consecutive experiments to evaluate efficacy of intramuscular (IM) or oral (PO)
delivery of ERA-g333a recombinant rabies virus vaccine to 57 big brown bats (Eptesicus fuscus).
Experiment
No.
bats
Cage
ID
Vaccine
routes
Vaccination
date
Infection date (day 21
postvaccination)
Experiment
end date
1 32 L, M, N, O, P, Q IM, PO 18 July 2007 8 August 2007 26 December 2007
2 25b R, S, T, U, Vc IM 18 October 2007 8 November 2007 27 March 2008
a ERA-g33 ¼ Evelyn-Rokitniki-Abelseth (ERA) strain of rabies virus with three nucleotides altered at position 333 of the ERA
glycoprotein gene.
b Three contact control bats with preexisting rabies virus-neutralizing antibody titers were challenged with rabies virus together with
other bats during experiment 2, within their original cage P, and are only included in the tally of experiment 1 bats.
c Five control bats that were experimentally challenged with rabies virus and housed in cage U were excluded from the analysis due to an
outbreak of a natural rabies virus infection within that cage.
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day 5 PI. Three additional bats in the cage
subsequently developed signs of clinical
rabies and were euthanized on days 50, 61,
and 91 PI, respectively. The only bat in cage
U that survived both the natural outbreak
and experimental RABV challenge demon-
strated a moderate level of RVNA (1.0 IU/
mL; Table 4) during baseline sampling and
remained seropositive at least until day 13 PI
and tested DFA negative upon censoring on
day 76 PI. Although all cage U bats were
challenged experimentally with RABV, the
four rabid bats in cage U were infected with a
big brown bat RABV that typed as an eastern
E. fuscus lineage (e1), along with the
experimental RABV challenge inoculum,
but the inoculum and outbreak viruses
consistently differed by 1.2% across 1.35 kb
of nucleoprotein sequence. Following dem-
onstration of a different RABV variant
infecting bats from this cage, we determined
that bat #65 had a minimum incubation
period of 60 d, considering the date of its
intake from the wild.
TABLE 2. Rabies virus-neutralizing antibody (IU/mL) detected in sera from 25 big brown bats (Eptesicus fuscus)
vaccinated intramuscularly with 53106 focus-forming units of ERA-g333a recombinant rabies virus vaccine (day
0). Twenty bats were challenged with 102.9 mouse intracerebral median lethal dose (MICLD50) of a big brown
bat rabies virus on day 21 postvaccination (PV), and five bats were not challenged. All bats were observed for 140
d postinfection. Sampling time points are labeled by PV day. Where two values are listed, bats were sampled on
different days between experiments.
Cage
Challenge dose
(log MICLD50)
b
Bat
ID
Rabies-neutralizing antibody (IU/mL) at days PV
(experiment 1/experiment 2)c
0 5 14/19 27/34 43/49 90/98 155/161
L 2.9 39 ,0.06 ,0.06 0.09 0.06 0.72 0.91 ND
L 2.9 496 ,0.06 ,0.06 1.62 .9.14 .9.14 5.08 ND
L 2.9 47 ,0.06 ,0.06 0.14 ,0.06 0.19 0.06 ND
L 2.9 48 ,0.06 ,0.06 1.42 ,0.06 ,0.06 ,0.06 0.19
M 2.9 51 ,0.06 0.11 1.14 0.40 1.92 3.41 2.96
M 2.9 55 ,0.06 ,0.06 3.29 0.57 1.14 2.10 3.25
M 2.9 38 ,0.06 1.70 .9.14 .9.14 .9.14 8.21 ND
M 2.9 41 ,0.06 0.29 0.57 2.53 1.73 2.46 6.10
R 2.9 66 ,0.06 ,0.06 0.40 0.64 1.48 1.34 0.07
R 2.9 12 ,0.06 ,0.06 0.10 ,0.06 ,0.06 0.12 ,0.06
R 2.9 19 ,0.06 ND ,0.06
R 2.9 26 ,0.06 ,0.06 ,0.06 ND ND 1.14 0.42
S 2.9 69 ,0.06 ,0.06 1.62 4.57 1.91 0.14 ,0.06
S 2.9 10 0.21 ND 1.94 3.29 3.75 0.29 0.07
S 2.9 20 ,0.06 ,0.06 0.08 0.10 0.14 ,0.06 0.09
S 2.9 22 ,0.06 ,0.06 ND 0.29 0.32 0.08 ,0.06
V 2.9 67 ,0.06 ,0.06 0.29 1.92 0.57 0.11 0.40
V 2.9 14 ,0.06 0.11 ND ND ND ND 0.30
V 2.9 15 ,0.06 ,0.06 ND 0.26 ND 0.13 0.36
V 2.9 23 0.87 0.29 .9.14 .9.14 ND 7.49
L NI 45 ,0.06 ,0.06 6.27 ,0.06 0.82 0.09 0.20
M NI 50 ,0.06 ,0.06 0.51 0.87 0.10 0.20 0.08
R NI 28 ,0.06 ,0.06 0.33 0.11 0.42 0.12 0.20
S NI 29 0.52 0.19 0.47 0.85 0.24 0.43 0.22
V NI 25 ,0.06 ,0.06 ,0.06 ND ND ,0.06 ND
a ERA-g33 ¼ Evelyn-Rokitniki-Abelseth (ERA) strain of rabies virus with three nucleotides altered at position 333 of the ERA
glycoprotein gene.
b NI ¼ not infected.
c ND ¼ not determined; insufficient blood sample from that bat-time point.
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We report nine nonspecific deaths during
this study: two euthanized due to poor
acclimation (#23, 25), one euthanized but
missing a test result (i.e., unknown cause;
#24), three found dead from unknown causes
(#19, 21, 49), one bat that was injured (#60),
one bat that displayed clinical signs consistent
with rabies but tested DFA negative (#37),
and one contact control bat that went missing
(#31). Other bats labeled as censored were
uninfected controls that remained clinically
normal during the observation period and
were transferred to other studies; they were
not tested for rabies during this study.
DISCUSSION
Although there are no efforts targeting
control of insectivorous bat rabies in the
Americas, the results of this study suggest
that the ERA-g333 vaccine may be safe,
immunogenic, and efficacious for big brown
bats, and possibly other bats, such as the
common vampire bat. While the PO dose of
ERA-g333 tested in this study was neither
immunogenic nor efficacious, it seems plausi-
ble that the dose may have been too low in
comparison to the doses typically used for PO
delivery to wild carnivores (Bankovskiy et al.
2008). In another rabies vaccination study
involving big brown bats, immunogenicity and
efficacy of a different live poxvirus vaccine
construct by oronasal route occurred (Stading
et al. 2017), and immunogenicity of a similar
poxvirus construct was also demonstrated
among Brazilian free-tailed bats (Tadarida
brasiliensis) when delivered by oronasal route
(Stading et al. 2016). We had low power to
detect any difference in survivorship between
PO vaccinates and controls, but the lack of
RVNA responses among PO vaccinates during
experiment 1 did not compel further replica-
tion of the treatment route during experiment
2. Future studies should consider PO testing
of vaccine in bats at a dose more comparable
to carnivores, although vaccine delivery vol-
ume constraints of working with some insec-
t i v o r o u s b a t s p e c i e s m a y r e q u i r e
concentration of vaccine stock, as previously
reported during a study with common vam-
TABLE 3. Rabies virus-neutralizing antibody (IU/mL) detected in sera from 10 big brown bats (Eptesicus fuscus)
vaccinated orally with 53106 focus-forming units of ERA-g333a recombinant rabies virus vaccine. Seven bats
were challenged with 102.9 mouse intracerebral median lethal dose (MICLD50) of a big brown bat rabies virus on
day 21 postvaccination (PV), and three bats were not challenged. All bats were observed for 140 d postinfection.
Sampling time points are labeled by PV day. Where two values are listed, bats were sampled on different days
between experiments.
Cage
Challenge dose
(log MICLD50)
b
Bat
ID
Rabies-neutralizing antibody (IU/mL) at days PV
(experiment 1/experiment 2)c
0 5 14/19 27/34 43/49 90/98 155/161
N 2.9 500 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06
N 2.9 52 ,0.06 ,0.06 ,0.06 ,0.06 ND
N 2.9 53 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06
N 2.9 59 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06
O 2.9 44 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06
O 2.9 43 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06
O 2.9 40 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06
O NI 60 ,0.06 ,0.06 ND
N NI 463 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06
O NI 61 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06
a ERA-g33 ¼ Evelyn-Rokitniki-Abelseth (ERA) strain of rabies virus with three nucleotides altered at position 333 of the ERA
glycoprotein gene.
b NI ¼ not infected.
c ND ¼ not determined; insufficient blood sample from that bat-time point.
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pire bats (Almeida et al. 2008). Similar to
observations from experimental studies with
common vampire bats and, more recently,
insectivorous bats (Almeida et al. 2005, 2008;
Stading et al. 2017), indirect routes of
vaccination are also critical to evaluate once
oral efficacy has been established, given the
potential utility of social grooming oral contact
behavior among gregarious bats to increase
vaccination coverage beyond what can be
achieved by direct delivery methods. Aerosol
delivery may be another potential route for
vaccinating wild bat populations, yet one study
reported the immunogenicity, but not the
efficacy, of an experimental aerosol vaccine
delivery method (Davis et al. 2007). Our study
suggests that live attenuated RABV constructs
traditionally used for ORV of wild carnivores
in North America and Europe may be
efficacious for bats as well.
Other important insights regarding big
brown bat RABV pathogenesis were made
during the study. First, several of the bats
that were collected from the wild presented
RVNA during baseline sampling, which is
consistent with observations of naturally
occurring abortive RABV infections in syl-
vatic reservoirs and demonstrates that sero-
negative results do not necessarily imply a
naı̈ve exposure history among wild-caught
mammals, as previously reported (Turmelle
et al. 2010). Several others that were
seronegative upon intake appeared to devel-
op an anamnestic response to vaccination or
challenge (i.e., RVNA seroconversion within
5–6 d PV or PI). The induction of a humoral
antibody response to rabies vaccination
typically takes 14–30 d to develop in response
to a primary exposure. Rapid induction of the
immune response within 5-6 d may be
inconsistent with a primary exposure. Fur-
thermore, naturally acquired RVNA (range:
0.2 to greater than 9.14 IU/mL) was protec-
tive against RABV challenge in four bats.
TABLE 4. Rabies virus-neutralizing antibody (IU/mL) detected in sera from 17 unvaccinated big brown bats
(Eptesicus fuscus) challenged with 102.9 mouse intracerebral median lethal dose (MICLD50) of a big brown bat
rabies virus on day 21 postvaccination (PV) and observed for 140 days postinfection. Sampling time points are
labeled by PV day. Where two values are listed, bats were sampled on different days between experiments.
Cage
Bat
ID
Rabies-neutralizing antibody (IU/mL) at days PV
(experiment 1/experiment 2)a
0 5 14/19 27/34 43/49 90/98 155/161
P 49 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06
P 58 ,0.06 ND ,0.06 ,0.06 ,0.06
Q 32 ,0.06 ND ,0.06 ,0.06
Q 34 ,0.06 ND ,0.06 ,0.06 ,0.06
Q 35 ,0.06 ND ,0.06 0.13 ,0.06 ND ND
Q 36 ,0.06 ND ,0.06 ,0.06 ,0.06 ,0.06 ,0.06
Q 37 ,0.06 ND ,0.06 ,0.06 ,0.06
T 465 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06 ND
T 16 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06
T 18 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06 ND ,0.06
T 24 ,0.06 ,0.06 ND ND ND
T 27 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06
U 65 ,0.06 ,0.06 ,0.06 ,0.06
U 11 ,0.06 ,0.06 ,0.06 ,0.06 ND
U 17 ,0.06 ,0.06 ,0.06 ND ,0.06 ,0.06
U 21 1.00 0.27 0.50 1.78 ND ND
U 30 ,0.06 ,0.06 ND ND ND
a ND ¼ not determined; insufficient blood sample from that bat-time point.
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TABLE 5. Survival outcomes among 39 big brown bats (Eptesicus fuscus) vaccinated with ERA-g333a
recombinant rabies virus vaccine by the intramuscular (IM) or oral routes, or unvaccinated controls (NV). On
day 21 postvaccination, all bats were experimentally challenged with 102.9 mouse intracerebral median lethal
dose (MICLD50) of a big brown bat rabies virus.
Experiment Cage Bat ID Vaccination route Final dispositionb
1 L 39 IM S
1 L 496 IM S
1 L 47 IM S
1 L 48 IM S
1 M 51 IM S
1 M 55 IM S
1 M 38 IM S
1 M 41 IM S
2 R 66 IM S
2 R 12 IM S
2 R 19 IM N
2 R 26 IM S
2 S 69 IM S
2 S 10 IM S
2 S 20 IM S
2 S 22 IM S
2 V 67 IM S
2 V 14 IM S
2 V 15 IM S
2 V 23 IM N
1 N 500 Oral S
1 N 52 Oral D(24)
1 N 53 Oral S
1 N 59 Oral S
1 O 44 Oral D(87)
1 O 43 Oral D(26)
1 O 40 Oral S
1 P 49 NV N
1 P 58 NV D(26)
1 Q 32 NV D(20)
1 Q 34 NV D(26)
1 Q 35 NV S
1 Q 36 NV S
1 Q 37 NV N
2 T 465 NV S
2 T 16 NV D(38)
2 T 18 NV S
2 T 24 NV ND
2 T 27 NV D(115)
a ERA-g33 ¼ Evelyn-Rokitniki-Abelseth (ERA) strain of rabies virus with three nucleotides altered at position 333 of the ERA
glycoprotein gene.
b S ¼ survived to 140 d postinfection and tested negative for rabies virus infection; N ¼ tested negative for rabies virus infection
(censored); D¼died from infection with rabies virus, with incubation period in parentheses; ND¼not determined, missing laboratory
result for bat that was censored on day 51 postinfection.
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Bats may be incubating RABV infection upon
collection from the wild, with potential for
bat-to-bat transmission in captive settings
and safety risks to humans and animals
(Shankar et al. 2004; Davis et al. 2012).
While we cannot conclusively establish that
natural RABV transmission occurred during
our study, it seems more parsimonious in
comparison to a hypothesis of independent
incubation of RABV infections in four bats in
a single cage. The outbreak in this study was
associated with an autumn collection of big
brown bats, a time of year where population
infection prevalence may be elevated
(George et al. 2011).
In conclusion, IM delivery of the ERA-g333
live attenuated recombinant RABV vaccine
was safe, immunogenic, and efficacious in
protecting big brown bats against a lethal
challenge, yet PO delivery was neither immu-
nogenic nor efficacious. However, it remains
possible that a higher vaccine dose by the PO
route may be effective. While broad-scale
delivery of vaccines to wild bats still presents
logistical challenges, additional studies testing
oral rabies vaccines in insectivorous and other
bats are warranted, particularly for key RABV
reservoir hosts.
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De Serres G, Dallaire F, Côte M, Skowronski DM. 2008.
Bat rabies in the United States and Canada from
1950 through 2007: Human cases with and without
bat contact. Clin Infect Dis 46:1329–1337.
Dean DJ, Abelseth MK, Atanasiu P. 1996. The fluorescent
antibody test. In: Laboratory techniques in rabies,
Meslin FX, Kaplan MM, Koprowski H, editors.
World Health Organization, Geneva, Switzerland,
pp. 88–93.
Dietzschold B, Wunner WH, Wiktor TJ, Lopes AD, Lafon
M, Smith CL, Koprowski H. 1983. Characterization
of an antigenic determinant of the glycoprotein that
correlates with pathogenicity of rabies virus. Proc
Natl Acad Sci U S A 80:70–74.
Fehlner-Gardiner C, Nadin-Davis S, Armstrong J, Mul-
doon F, Bachmann P, Wandeler A. 2008. ERA
vaccine-derived cases of rabies in wildlife and
domestic animals in Ontario, Canada, 1989–2004. J
Wildl Dis 44:71–85.
Franka R, Wu X, Jackson FR, Velasco-Villa A, Palmer DP,
Henderson H, Hayat W, Green DB, Blanton JD,
Greenberg L, et al. 2009. Rabies virus pathogenesis
in relationship to intervention with inactivated and
attenuated rabies vaccines. Vaccine 27:7149–7155.
George DB, Webb CT, Farnsworth ML, O’Shea TJ,
Bowen RA, Smith DL, Stanley TR, Ellison LE,
Rupprecht CE. 2011. Host and viral ecology
determine bat rabies seasonality and maintenance.
Proc Natl Acad Sci U S A 108:10208–10213.
Gilbert AT. 2018. Rabies virus vectors and reservoir
species. Rev Sci Tech 37:371–384.
Hampson K, Coudeville L, Lembo T, Sambo M, Kieffer
A, Attlan M, Barrat J, Blanton JD, Briggs DJ,
Cleaveland S, et al. 2015. Estimating the global
burden of endemic canine rabies. PLoS Negl Trop
Dis 9:e0003709.
Jackson FR, Turmelle AS, Farino DM, Franka R,
McCracken GF, Rupprecht CE. 2008. Experimental
rabies virus infection of big brown bats (Eptesicus
fuscus). J Wildl Dis 44:612–621.
Kuzmin IV, Shi M, Orciari LA, Yager PA, Velasco-Villa A,
Kuzmina NA, Streicker DG, Bergman DL, Rup-
precht CE. 2012. Molecular inferences suggest
multiple host shifts of rabies viruses from bats to
mesocarnivores in Arizona during 2001–2009. PLoS
Pathog 8:e1002786.
Lafay F, Benejean J, Tuffereau C, Flamand A, Coulon P.
1994. Vaccination against rabies: Construction and
characterization of SAG2, a double avirulent deriva-
tive of SAD Bern. Vaccine 12:317–320.
Le Blois H, Tuffereau C, Blancou J, Artois M, Aubert A,
Flamand A. 1990. Oral immunization of foxes with
avirulent rabies virus mutants. Vet Microbiol 23:259–
266.
Leslie MJ, Messenger S, Rohde RE, Smith J, Cheshier R,
Hanlon C, Rupprecht CE. 2006. Bat-associated
rabies virus in skunks. Emerg Infect Dis 12:1274–
1277.
MacInnes CD, Smith SM, Tinline RR, Ayers NR,
Bachmann P, Ball DG, Calder LA, Crosgrey SJ,
Fielding C, Hauschildt P, et al. 2001. Elimination of
rabies from red foxes in eastern Ontario. J Wildl Dis
37:119–132.
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